---
schema_version: "secwatch.filing_event.v1"
accession: "0000885725-26-000029"
form_type: "8-K"
ticker: "BSX"
cik: "0000885725"
company_name: "BOSTON SCIENTIFIC CORP"
filed_at: "2026-03-30T23:59:59+00:00"
generated_at: "2026-05-15T08:30:02.154047+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Boston Scientific reports positive HI-PEITHO and CHAMPION-AF trial results

## Summary
- HI-PEITHO: EKOS plus anticoagulation reduced primary endpoint events by 61% vs anticoagulation alone (4.0% vs 10.3%, P=0.005).
- HI-PEITHO: No episodes of intracranial bleeding through 30 days; results published in NEJM.
- CHAMPION-AF: WATCHMAN FLX showed 45% relative reduction in non-procedural major bleeding vs NOACs (10.9% vs 19.0%, P<0.001).
- CHAMPION-AF: Primary efficacy endpoint met with non-inferiority to NOACs for stroke, CV death, or systemic embolism (5.7% vs 4.8%).
- Both trials presented at ACC.26 and simultaneously published in The New England Journal of Medicine; data support expanded indications.

## SEC filing metadata
- accession: 0000885725-26-000029
- form_type: 8-K
- ticker: BSX
- cik: 0000885725
- company_name: BOSTON SCIENTIFIC CORP
- filed_at: 2026-03-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/885725/000088572526000029/0000885725-26-000029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/885725/000088572526000029/bsx-20260328.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000885725-26-000029
- JSON: https://secwatch.observer/filing/0000885725-26-000029.json
- Plain text: https://secwatch.observer/filing/0000885725-26-000029.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.